Translational research in complex etiopathogenesis and therapy of hematological malignancies: the specific role of tyrosine kinases signaling and inhibition.
During the recent genomics and proteomics era, high-resolution, genome-wide approaches have revealed numerous promising new drug targets and disease biomarkers, accelerating and emphasizing the need for targeted molecular therapy compounds. Significant progress has been made in understanding the pathogenesis of hematological malignancies there by, revealing new drug targets. Introduction of multiple new technologies in cancer research have significantly improved the drug discovery process, leading to key success in targeted cancer therapeutics, including tyrosine kinase inhibitors. The studies of receptor tyrosine kinases and their role in malignant transformation are already translated from the preclinical level (cell-based and animal models) to clinical studies, enabling the more complete understanding of tumor cell biology and improvement of tumor therapy.
Stankov
Karmen
K
Department of Biochemistry, Medical faculty, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia. stankov@cng.fr
Stankov
Suncica
S
Popović
Stevan
S
D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011494:Protein Kinases / Q000737:chemistry / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects*; D057170:Translational Research, Biomedical
D047428:Protein Kinase Inhibitors; D011494:Protein Kinases